Forest Laboratories (NYSE: FRX) develops branded and generic drug products, as well as non-prescription pharmaceuticals. Offerings include Lexapro, for the treatment of depression, Namenda for Alzheimer's disease, Benicar for hypertension, and Campral for the maintenance of alcohol abstinence. Other products include treatments for diaper rash, colic, cystic fibrosis, hypertension, eczema and psoriasis. The company is working in collaboration with other firms to develop treatments for asthma, schizophrenia, chronic pain and anxiety. Eli Lilly (NYSE: LLY) and Pfizer (NYSE: PFE) are major competitors.

Forest Labs pleased investors last week when it reported Q3 EPS of 96 cents and revenues of $998.2 million. Analysts had been looking for 75 cents and $946.6 million. Management also guided FY08 EPS to $3.35-$3.45, above prior guidance of $3.10-$3.20 and Street consensus of $3.06. The CEO noted that the company expects to report clinical trial results for several late-stage products during the remainder of the calendar year. Lehman Brothers, Roth Capital and AmTech Research subsequently reiterated "buy" ratings on the stock. Raymond James initiated the shares with a "strong buy." The shares popped into a bullish "flag" consolidation pattern on the news. Prices frequently exit flags moving in the same direction they were traveling on entry. In this case, that would be to the upside.

Altogether, brokers now recommend the issue with eleven "strong buys," ten "buys," twelve "holds" and one "sell." The stock's Price Book ratio (3.90), EPS Growth rate (23.35%), Operating Margin (22.46%) and Net Profit Margin (14.94%) compare favorably with industry, sector and S&P 500 averages. Institutional investors hold about 95% of the outstanding shares. The stock is one of those used to calculate the S&P 500 Index. Over the past 52 weeks, it has traded between $34.89 and $57.97. A stop-loss of $33.95 looks good here.

Larry Schutts is a contributing editor for Theflyonthewall.com and the Vice-President of Stockwinners.com. He does not hold positions in any of the stocks mentioned above.

MOST NOTEWORTHY: Refiners, MasTec, Cognos, Forest Labs and Reuters Group were today's noteworthy upgrades:

• Bernstein upgraded shares of Marathon Oil Corporation (NYSE: MRO), Tesoro Corporation (NYSE: TSO), Sunoco Incorporated (NYSE: SUN) and Valero Energy Corporation (NYSE: VLO) to Market Perform from Underperform.
• MasTec Incorporated (NYSE: MTZ) was upgraded to Buy from Accumulate at Think Equity and to Buy from Hold at SMH Capital on valuation following yesterday's sell-off.
• JP Morgan upgraded shares of Cognos Incorporated (NASDAQ: COGN) to Overweight from Neutral citing solid end demand, expanded sales capacity, indications that C8 adoption should see an uptick, and the Applix Inc (NASDAQ: APLX) acquisition.
• Forest Laboratories Inc (NYSE: FRX) was upgraded to Buy from Hold at Jefferies, as the firm believes Forest's victory in the Lexapro patent case eliminates a major overhang and returns the focus to the company's pipeline.
• Lehman upgraded shares of Reuters Group (NASDAQ: RTRSY) to Overweight from Equal Weight to reflect benefits from the company's merger with Thomson Corporation (NYSE: TOC).

OTHER UPGRADES:

• UBS upgraded shares of General Mills Inc (NYSE: GIS) to Buy from Neutral.
• Thornburg Mortgage (NYSE: TMA) was upgraded to Sector Perform from Underperform at RBC Capital Markets.
• CIBC World Markets upgraded EDO Corporation (NYSE: EDO) to Sector Outperformer from Sector Performer.
• Bernstein upgraded shares of Rio Tinto (NYSE: RTP) to Outperform from Market Perform and shares of Anglo American (NASDAQ: AAUK) to Market Perform from Underperform.

Wondering whether you should consider some shifts in your portfolio now that the Democrats have control of Congress? You may want to watch the moves of mutual fund managers to get some clues about which types of stocks might gain and which may lose with the shift of power in Washington.

MarketWatch gave its readers an excellent overview of winners and losers expected after that the Democrats control the House based on interviews with some key mutual fund managers. Many managers expect that the big losers will be defense and some parts of the health industry. Big gainers could be Fannie Mae and Freddie Mac because the Democrats are less likely to put caps on their growth.

Republicans pressured Fannie Mae (FNM) and Freddie Mac (FRE) to slow their growth and hold fewer mortgages on their balance sheets. That pressure will likely ease under Democratic control. John Schneider, portfolio manager of Touchstone Large Cap Value Fund (TLCAX) told Marketwatch, "We see substantial upside now for each company's earnings and stock prices. As new money comes in, we're anticipating adding to existing positions in both."